Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine
Abstract
Objective: The objective of this study was to investigate quality of life (QoL) in patients with Graves' disease treated with radioiodine or antithyroid drugs. Design and methods: The design of the study consists of an open, prospective, randomized multicenter trial between radioiodine and medical treatment. A total of 308 patients were included in the study group: 145 patients in the medical group and 163 patients in the radioiodine group. QoL was measured with a 36-item Short Form Health Status Survey questionnaire (SF-36) at six time points during the 48-month study period. Results: Patient who developed or got worse of thyroid-associated ophthalmopathy (TAO) at any time point during the 4-year study period (TAO group) had lower QoL when no respect was paid to the mode of treatment. TAO occurred in 75 patients who had radioiodine treatment at some time point during the study period as compared with TAO in 40 medically treated patients (P<0.0009). Comparisons between the group of patients who have had TAO versus the group without TAO, in relation to treatments and time, showed significantly decreased QoL scores for the TAO groups at several time points during the study. In patients without TAO, there were no differences in QoL related to mode of treatment. Conclusions: The QoL in patients with Graves' ophthalmopathy was similar in radioiodine and medically treated patients, but patients who developed or had worsening of TAO had decreased QoL independent of mode of treatment. Furthermore, patients with TAO recovered physically within 1 year but it took twice as long for them to recover mentally.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Quality of life is clearly impaired by GO.
“Quality of life is clearly impaired by GO (526).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [526]
Cites
(1992) · PubMed · Cited by 33,716 · see citing works
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033 · see citing works
Sullivan, M., Karlsson, J., & Ware, J. E. (1995) · Social Science & Medicine · doi:10.1016/0277-9536(95)00125-q · Cited by 1,315 · see citing works
Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy
Bartalena, L., Marcocci, C., Bogazzi, F., Manetti, L., Tanda, M. L., Dell'Unto, E., Bruno-Bossio, G., Nardi, M., Bartolomei, M. P., Lepri, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380201 · Cited by 715 · see citing works
Pathogenesis of Graves' Ophthalmopathy
Epstein, F. H., Bahn, R. S., & Heufelder, A. E. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292007 · Cited by 610 · see citing works
Occurrence of Ophthalmopathy after Treatment for Graves' Hyperthyroidism
Tallstedt, L., Lundell, G., Tørring, O., Wallin, G., Ljunggren, J.-G., Blomgren, H., & Taube, A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206253262603 · Cited by 521 · see citing works
Self-citationThe Swedish SF-36 Health Survey III. Evaluation of Criterion-Based Validity
Sullivan, M., & Karlsson, J. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00102-4 · Cited by 480 · see citing works
Törring, O., Tallstedt, L., Wallin, G., Lundell, G. E. F., Ljunggren, J. ‐., Taube, A., Sääf, M., & Hamberger, B. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.8.8768863 · Cited by 311 · see citing works
Self-citationTräisk, F., Tallstedt, L., Abraham-Nordling, M., Andersson, T., Berg, G., Calissendorff, J., Hallengren, B., Hedner, P., Lantz, M., Nyström, E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0747 · Cited by 262 · see citing works
Self-citationGerding, M., Terwee, C., Dekker, F., Koornneef, L., Prummel, M., & Wiersinga, W. (1997) · Thyroid · doi:10.1089/thy.1997.7.885 · Cited by 233 · see citing works
Acharya, S., Avenell, A., Philip, S., Burr, J. M., Bevan, J. S., & Abraham, P. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03279.x · Cited by 198 · see citing works
The Swedish SF-36 Health Survey II. Evaluation of Clinical Validity
Persson, L., Karlsson, J., Bengtsson, C., Steen, B. C., & Sullivan, M. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00101-2 · Cited by 197 · see citing works
Abraham-Nordling, M., Törring, O., Hamberger, B., Lundell, G., Tallstedt, L., Calissendorff, J., & Wallin, G. (2005) · Thyroid · doi:10.1089/thy.2005.15.1279 · Cited by 163 · see citing works
Self-citationKung, A. W. C., Yau, C., & Cheng, A. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.2.7913934 · Cited by 139 · see citing works
Long-term residual complaints and psychosocial sequelae after remission of hyperthyroidism.
Fahrenfort, J. J., Wilterdink, A. M. L., & van der Veen, E. A. (2000) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(99)00050-5 · Cited by 130 · see citing works
Long-term effects of Graves' ophthalmopathy on health-related quality of life.
Terwee, C., Wakelkamp, I., Tan, S. H., Dekker, F., Prummel, M., & Wiersinga, W. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460751 · Cited by 120 · see citing works
Ljunggren, J., Törring, O., Wallin, G., Taube, A., Tallstedt, L., Hamberger, B., & Lundell, G. E. F. (1998) · Thyroid · doi:10.1089/thy.1998.8.653 · Cited by 100 · see citing works
Self-citationPsychosocial Factors in Subjects with Thyroid-Associated Ophthalmopathy
Kahaly, G. J., Hardt, J., Petrak, F., & Egle, U. T. (2002) · Thyroid · doi:10.1089/105072502753600205 · Cited by 69 · see citing works
Incidence of hyperthyroidism in Stockholm, Sweden, 2003–2005.
Abraham‐Nordling, M., Törring, O., Lantz, M., Hallengren, B., Ohrling, H., Lundell, G. E. F., Calissendorff, J., Jörneskog, G., & Wallin, G. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0877 · Cited by 50 · see citing works
Self-citationTherapeutic controversies. Radioiodine therapy does not aggravate Graves' ophthalmopathy.
Gorman, C. A. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.2.7852485 · Cited by 47 · see citing works
Egle, U. T., Kahaly, G. J., Petrak, F., Hardt, J., Batke, J., Best, J. D., & Rothenbacher, M. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1212177 · Cited by 30 · see citing works
Lantz, M., Abraham‐Nordling, M., Svensson, J., Wallin, G., & Hallengren, B. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0548 · Cited by 27 · see citing works
Self-citationHYPOTHYROIDISM IN PROGRESSIVE OPHTHALMOPATHY OF GRAVES‘ DISEASE
Almqvist, S., & Algvere, P. V. (1972) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.1972.tb06615.x · Cited by 24 · see citing works
DECREASING INCIDENCE OF THYROTOXICOSIS IN AN ENDEMIC GOITRE INLAND AREA OF SWEDEN
Lundgren, E., & Christensen, S. B. (1990) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1990.tb00473.x · Cited by 23 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., et al. (2016) · Thyroid® · doi:10.1089/thy.2016.0229 · Cited by 2,938 · see citing works
Franklyn, J. A., & Boelaert, K. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60782-4 · Cited by 262 · see citing works
Quality of life in Graves’ ophthalmopathy
Wiersinga, W. M. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.11.001 · Cited by 136 · see citing works
Quality of life in thyroid eye disease: impact of quality of care
Estcourt, S., Quinn, A. G., & Vaidya, B. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0055 · Cited by 119 · see citing works
The Long-Term Outcome of Treatment for Graves' Hyperthyroidism
Sjölin, G., Holmberg, M., Törring, O., Byström, K., Khamisi, S., de Laval, D., Abraham‐Nordling, M., Calissendorff, J., Lantz, M., Hallengren, B., et al. (2019) · Thyroid · doi:10.1089/thy.2019.0085 · Cited by 106 · see citing works
Self-citationTörring, O., Watt, T., Sjölin, G., Byström, K., Abraham‐Nordling, M., Calissendorff, J., Cramon, P. K., Nyström, H. F., Hallengren, B., Holmberg, M., et al. (2019) · Thyroid · doi:10.1089/thy.2018.0315 · Cited by 104 · see citing works
Self-citationGenovese, B. M., Noureldine, S. I., Gleeson, E., Tufano, R. P., & Kandil, E. H. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2606-x · Cited by 97 · see citing works
Villagelin, D., Romaldini, J. H., dos Santos, R. B., Milkos, A. B. B. P., & Ward, L. S. (2015) · Thyroid · doi:10.1089/thy.2015.0195 · Cited by 98 · see citing works
Radioiodine therapy versus antithyroid medications for Graves' disease
Ma, C., Xie, J., Wang, H., Li, J., & Chen, S. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010094.pub2 · Cited by 48 · see citing works
Treating the thyroid in the presence of Graves’ ophthalmopathy
Hegedűs, L. D., Bonnema, S. J., Smith, T. J., & Brix, T. H. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.09.005 · Cited by 37 · see citing works
Wang, J., & Lan, Q. (2016) · British Journal of Radiology · doi:10.1259/bjr.20160418 · Cited by 33 · see citing works
What Are the Psychosocial Outcomes of Treatment for Thyroid Eye Disease? A Systematic Review
Lawes-Wickwar, S., McBain, H. B., Ezra, D. G., Hirani, S. P., Rose, G. E., & Newman, S. P. (2014) · Thyroid · doi:10.1089/thy.2014.0037 · Cited by 32 · see citing works
Outcomes of Patients With Graves Disease 25 Years After Initiating Antithyroid Drug Therapy
Stokland, A. M., Austdal, M., Nedrebø, B. G., Carlsen, S., Hetland, H. B., Breivik, L., Ueland, H. O., Watt, T., Cramon, P. K., Løvås, K., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad538 · Cited by 28 · see citing works
Iacobæus, L., & Sahlin, S. (2016) · Orbit · doi:10.1080/01676830.2016.1176049 · Cited by 28 · see citing works
Measuring Health-Related Quality of Life in Thyroid Eye Disease
Sharma, A. R., Stan, M. N., & Rootman, D. B. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac230 · Cited by 28 · see citing works
Villagelin, D., Romaldini, J. H., Carlini, J. D. A., dos Santos, R. B., Milkos, A. B. B. P., Teixeira, P. F. D. S., & Ward, L. S. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00192 · Cited by 24 · see citing works
Lahooti, H., Cultrone, D., Edirimanne, S., Walsh, J. P., Delbridge, L., Cregan, P., Wall, J. R., & Champion, B. L. (2015) · Clinical ophthalmology · doi:10.2147/opth.s87972 · Cited by 11 · see citing works
Validation and cross-cultural adaptation of the questionnaire ThyPRO in thyroid patients in Serbia
Bukvić, B., Zivaljevic, V. R., Grujičić, S. Š., Diklić, A., Tausanovic, K. M., & Paunovic, I. R. (2015) · Vojnosanitetski pregled · doi:10.2298/vsp131112035b · Cited by 9 · see citing works
Long term outcome after toxic nodular goitre
Sjölin, G., Watt, T., Byström, K., Calissendorff, J., Cramon, P. K., Nyström, H. F., Hallengren, B., Holmberg, M., Khamisi, S., Lantz, M., et al. (2022) · Thyroid Research · doi:10.1186/s13044-022-00138-0 · Cited by 7 · see citing works
Self-citationGraves’ Orbitopathy Models: Valuable Tools for Exploring Pathogenesis and Treatment
Wang, L., Zhang, M., Wang, Y., & Shi, B. (2023) · Hormone and Metabolic Research · doi:10.1055/a-2161-5417 · Cited by 6 · see citing works
Radioiodine therapy versus anti-thyroid medications for Graves' disease
Ma, C., Xie, J., Wang, H., Li, J., & Chen, S. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010094 · Cited by 6 · see citing works
Morris, O. C., Schebitz-Walter, K., Telemo, E., & Hintschich, C. R. (2016) · Orbit · doi:10.1080/01676830.2016.1193531 · Cited by 5 · see citing works
The evolving landscape of thyroid eye disease: present and future
Toro-Tobón, D., & Stan, M. N. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf156 · Cited by 4 · see citing works
Psychometric properties of EQ-5D-5L for use in patients with Graves’ disease
Liu, X., Chan, W. W., Tang, E. H. M., Suen, A. H., Fung, M. M., Woo, Y. C., Liu, S. Y., Lam, C. L. K., Luo, N., Wong, C. K. H., et al. (2023) · Health and Quality of Life Outcomes · doi:10.1186/s12955-023-02177-z · Cited by 4 · see citing works
Steffens, B., Koch, G., Gaechter, P., Claude, F., Gotta, V., Bachmann, F., Schropp, J., Janner, M., l’Allemand, D., Konrad, D., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1099470 · Cited by 4 · see citing works
Schovánek, J., Radvanský, M., Karhanová, M., Bolacka, M., Pekarova, K., Dohnal, R., Radvanský, M., Kudělka, M., Kriegová, E., & Karásek, D. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.02.003 · Cited by 2 · see citing works
Cultrone, D. (2014) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr/2014/9504 · Cited by 2 · see citing works
Quality of Life Studies in Thyroid-Associated Orbitopathy
Rødahl, E., Sahlin, S., & Mourits, M. P. (2024) · Springer eBooks · doi:10.1007/978-3-031-39638-0_41 · Cited by 1 · see citing works
Quality of Life in Graves’ Ophthalmopathy
Bradley, E. A., & Fuller, M. L. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2534-6_22 · Cited by 1 · see citing works
Lee, S. Y. (2019) · Clinical Thyroidology · doi:10.1089/ct.2019;31.144-147 · Cited by 1 · see citing works
Best Practice & Research Clinical Endocrinology & Metabolism
der Grinten, H. L. C., Otten, B. J., Stikkelbroeck, M., Sweep, F. C. G. J., & Hermus, A. R. M. M. (2009)
Updates of Radioiodine Treatment for Graves' Disease
Jeong, S. Y. (2019) · International Journal of Thyroidology · doi:10.11106/ijt.2019.12.2.85
Tanda, M. L. (2020) · L Endocrinologo · doi:10.1007/s40619-020-00770-8
Additional file 1 of Psychometric properties of EQ-5D-5L for use in patients with Graves’ disease
Liu, X., Chan, W. W., Tang, E. H. M., Suen, A. H., Fung, M. M., Woo, Y. C., Liu, S. Y., Lam, C. L., Luo, N., Wong, C. K., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23949552
- Authors
- Abraham-Nordling, M., Wallin, G., Träisk, F., Berg, G., Calissendorff, J., Hallengren, B., Hedner, P., Lantz, M., Nyström, E., Åsman, P., Lundell, G., Törring, O., & _, _.
- Affiliations
- Karolinska Institutet (SE)
- Sahlgrenska University Hospital (SE)
- Karolinska University Hospital (SE)
- Skåne University Hospital (SE)
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-10
- Volume
- 163
- Issue
- 4
- Pages
- 651-657
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2144205518
- Cited by
- 35
- References
- 24
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 6 · 2022: 2 · 2020: 1 · 2019: 5 · 2016: 5 · 2015: 4 · 2014: 2 · 2012: 5
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Ophthalmology and Eye Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- Graves' ophthalmopathy, Graves' disease, quality of life, radioiodine therapy, antithyroid drugs, treatment comparison, SF-36
- MeSH terms
- Adult, Aged, Female, Graves Disease, Humans, Iodine Radioisotopes, Male, Methimazole, Middle Aged, Quality of Life, Antithyroid Agents, Treatment Outcome, Graves Ophthalmopathy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
